• Login
    View Item 
    •   DSpace Home
    • Centro Académico de Salud (CAS)
    • Hospital Universitario Austral -HUA-
    • Investigación Aplicada
    • View Item
    •   DSpace Home
    • Centro Académico de Salud (CAS)
    • Hospital Universitario Austral -HUA-
    • Investigación Aplicada
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina

    Thumbnail
    View/Open
    IA - Piñero (133.3Kb)
    Date
    2018-04-30
    Author
    Piñero, Federico.
    Marciano, Sebastián.
    Fernández, Nora.
    Silva, Jorge.
    Zambelo, Yanina.
    Cobos, Manuel.
    Zerega, Alina.
    et al.
    Metadata
    Show full item record
    Abstract
    Abstract Background and aim Adherence to the Barcelona Clinic Liver Cancer (BCLC) staging algorithm for the treatment of hepatocellular carcinoma is challenging in the daily practice. We aimed to analyze adherence to BCLC along with its effect on patient survival. Patients and methods A cohort study was conducted in 14 hospitals from Argentina including patients with newly diagnosed hepatocellular carcinoma (2009–2016). Adherence was considered when the first treatment was the one recommended by the BCLC. Results Overall, 708 patients were included. At diagnosis, BCLC stages were as follows: stage 0 4%, A 43%, B 22%, C 9% and D 22%. Overall, 53% of the patients were treated according to BCLC, 24% were undertreated, and 23% overtreated. Adherence to BCLC increased to 63% in subsequent treatments. Independent factors associated with adherence to BCLC were the presence of portal hypertension [odds ratio: 1.63; 95% confidence interval (CI): 1.11–2.39] and BCLC stage C (odds ratio: 0.32; 95% CI: 0.12–0.72). In a multivariable model adjusting for portal hypertension and BCLC stages, adherence to BCLC showed improved survival (hazard ratio: 0.67; 95% CI: 0.52–0.87). Conclusion Adherence to BCLC represents a challenge in the daily practice, with almost half of the patients being treated accordingly, showing that the decision-making process should be tailored to each individual patient.
    URI
    https://riu.austral.edu.ar/handle/123456789/956
    Collections
    • Investigación Aplicada

    xmlui.dri2xhtml.structural.info-link
    Licencia Creative Commons
    xmlui.dri2xhtml.structural.contact-link1 - xmlui.dri2xhtml.structural.contact-link2
    xmlui.dri2xhtml.structural.info-link2
     

     


    xmlui.dri2xhtml.structural.info-link
    Licencia Creative Commons
    xmlui.dri2xhtml.structural.contact-link1 - xmlui.dri2xhtml.structural.contact-link2
    xmlui.dri2xhtml.structural.info-link2